One in 8 women will be diagnosed with breast cancer. It is the leading cancer diagnosis in women. And, while less common, 1 in 75 women will be diagnosed with ovarian cancer and two-thirds will lose their life as a result of their diagnosis. However, when caught early, the 5-year survival rate for breast and ovarian cancer is greater than 93 percent.
Visit Assess Your Risk and take a 19-question quiz to better understand your baseline risk of breast and ovarian cancer.
Bright Pink, a national nonprofit focused on the prevention and early detection of breast and ovarian cancer, wants to help you understand how your personal health history, family health history, and lifestyle all work together to influence your risk of these cancers.
FDA to Review Inavolisib Combo for HR-Positive, HER2-Negative Breast Cancer
May 22nd 2024The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Read More
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Listen